Amphastar Pharmaceuticals logo
Amphastar Pharmaceuticals AMPH
$ 21.68 1.4%

Annual report 2025
added 02-26-2026

report update icon

Amphastar Pharmaceuticals Cash Flow 2011-2026 | AMPH

Annual Cash Flow Amphastar Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

156 M 213 M 184 M 89.2 M 98 M 57.3 M 41.8 M 38.2 M 39.2 M 38.6 M 10.7 M - - - -

Depreciation & Amortization

31.6 M 28.2 M 25.2 M 23.8 M 10.2 M 9.03 M 7.06 M 6.05 M 6.42 M 12.2 M 11.3 M 12.5 M 11.2 M 9.66 M -

Accounts Payables

32.6 M 30.5 M 25.4 M 20.5 M 22.2 M 24.4 M 25.1 M 31.3 M 16.6 M 16.2 M 13.9 M 10.2 M - - -

Accounts Receivables

144 M 136 M 115 M 88.8 M 78.8 M 66 M 45.4 M 52.2 M 36 M 26.8 M 33.2 M 22.9 M - - -

Total Inventories

177 M 154 M 106 M 104 M 92.8 M 96.8 M 111 M 69.3 M 63.6 M 79.8 M 70.7 M 82.3 M - - -

All numbers in USD currency

Quarterly Cash Flow Amphastar Pharmaceuticals

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - 35.1 M - - - 55.3 M - - - 40.4 M - - 53.6 M 50.8 M - - 55 M 22.8 M - 40.4 M 31.6 M 1.48 M - 36.1 M 48.1 M -3.61 M - 28.7 M 12.9 M 8.36 M - 29.4 M 27 M 22.4 M - 24.6 M - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

14.1 M 14.6 M 7.37 M - 13.4 M 13.1 M 6.82 M - 9.62 M 3.06 M 3.4 M - 3.42 M 3 M 2.74 M - 2.5 M 2.64 M 2.48 M - 2.46 M 2.03 M 2.05 M - 1.7 M 1.66 M 1.64 M - 10.4 M 6.51 M 3.06 M - 9.67 M 6.24 M 3.1 M - 9.01 M 6 M 2.95 M - 8.52 M 5.63 M 2.77 M - 9.24 M 6.04 M 2.94 M - 8.19 M 5.4 M - - - - - - - - -

Accounts Payables

40.5 M 41.9 M 52.8 M 30.5 M 34.1 M 31.8 M - 25.4 M 32 M - 22 M 20.5 M - 31.1 M 23.8 M 22.2 M 21.7 M 27.8 M 23 M 24.4 M 24.4 M 24.4 M 24.4 M 25.1 M 25.1 M 25.1 M 25.1 M 31.3 M 31.3 M 31.3 M 31.3 M 16.6 M 16.6 M 16.6 M 16.6 M 19.9 M 16.2 M 16.2 M 16.2 M 13.9 M 13.9 M 13.9 M 13.9 M 10.2 M 10.2 M 10.2 M 10.2 M 20.4 M 20.4 M 20.4 M - - - - - - - - -

Accounts Receivables

147 M 133 M 145 M 136 M 140 M 131 M - 115 M 119 M - 101 M 88.8 M - 80.8 M 73.2 M 78.8 M 78.1 M 67.9 M 77.9 M 66 M 66 M 66 M 66 M 45.4 M 45.4 M 45.4 M 45.4 M 52.2 M 52.2 M 52.2 M 52.2 M 36 M 36 M 36 M 36 M 26.8 M 26.8 M 26.8 M 26.8 M 33.2 M 33.2 M 33.2 M 33.2 M 22.9 M 22.9 M 22.9 M 22.9 M 24.6 M 24.6 M 24.6 M - - - - - - - - -

Total Inventories

186 M 192 M 185 M 154 M 130 M 122 M - 106 M 110 M - 104 M 104 M - 98.7 M 95.1 M 92.8 M 100 M 97.9 M 97.1 M 96.8 M 96.8 M 96.8 M 96.8 M 111 M 111 M 111 M 111 M 69.3 M 69.3 M 69.3 M 69.3 M 63.6 M 63.6 M 63.6 M 63.6 M 79.8 M 79.8 M 79.8 M 79.8 M 70.7 M 70.7 M 70.7 M 70.7 M 82.3 M 82.3 M 82.3 M 82.3 M 69.9 M 69.9 M 69.9 M - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Amphastar Pharmaceuticals, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.73 0.42 % $ 761 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 3.4 4.29 % $ 342 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 333.39 -1.77 % $ 43.7 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.17 3.93 % $ 5.22 M israelIsrael
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.73 3.04 % $ 8.97 B australiaAustralia
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 7.42 -15.1 % $ 73.3 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 99.47 1.08 % $ 27.2 B germanyGermany
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
- - $ 399 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.24 2.17 % $ 453 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.58 -2.03 % $ 3.13 B usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.49 0.68 % $ 397 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
$ 2.75 4.16 % $ 1.22 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
- - $ 310 B britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 2.17 5.85 % $ 451 M usaUSA